FDA Approves Belantamab Mafodotin-blmf for R/R Multiple Myeloma

Belantamab mafodotin-blmf (BLENREP®, GlaxoSmithKline) was recently FDA approved for adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have previously failed four therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Approval was based on DREAMM-2 (NCT03525678), an open-label, multicenter trial that enrolled 293 patients with R/R MM with disease progression after three or more lines of prior therapy and who were refr...
Continue reading

Oral Decitabine/Cedazuridine for MDS: Olatoyosi Odenike, MD

In this interview, Olatoyosi Odenike, MD, speaks with i3 Health about the approval of oral decitabine/cedazuridine (Inqovi®, Astex Pharmaceuticals, Inc.) for adult patients with myelodysplastic syndromes (MDS). Dr. Odenike, Director of the Leukemia Program at the University of Chicago and an investigator of one of the clinical trials on which the approval was based, discusses the challenges of treating patients with MDS and the significance of the approval of oral decitabine/cedazuridine. What a...
Continue reading

Transplant-Ineligible Diffuse Large B-Cell Lymphoma: Tafasitamab/Lenalidomide Approved

The FDA has granted accelerated approval to tafasitamab-cxix (Monjuvi®, MorphoSys US Inc.) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, who are ineligible for autologous stem cell transplantation. The approval of tafasitamab, a CD19-directed cytolytic antibody, is based on efficacy data from the single-arm, international phase 2 L-MIND trial (NCT02399085), wh...
Continue reading

First CAR T-Cell Therapy Approved for Mantle Cell Lymphoma

The FDA has now granted accelerated approval to brexucabtagene autoleucel (TecartusTM, Kite Pharma, formerly known as KTE-X19) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL). Brexucabtagene autoleucel, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, is the first CAR T-cell therapy approved for this rare type of B-cell non-Hodgkin lymphoma. Efficacy was evaluated in the multicenter, open-label phase 2 ZUMA-2 trial (NCT02601313), which enrolled 7...
Continue reading

Multiple Myeloma: Adding Daratumumab to Carfilzomib/Dexamethasone Enhances Efficacy

Results from the phase 3 CANDOR trial show that for relapsed/refractory multiple myeloma, adding daratumumab (D) to carfilzomib/dexamethasone (Kd) increases efficacy compared with Kd alone. "Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma," write the study investigators in their publication in The Lancet, led by Meletios Dimopoulos, MD, Professor and Chairman of Clinical Therapeutics at the Na...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.